Skip to main content
Erschienen in: Journal of Cancer Survivorship 1/2016

01.02.2016

Assessing the prevalence of compromised bone health among overweight and obese African-American breast cancer survivors: a case–control study

verfasst von: Patricia Sheean, Huifang Liang, Linda Schiffer, Claudia Arroyo, Karen Troy, Melinda Stolley

Erschienen in: Journal of Cancer Survivorship | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Osteoporosis increases the risk of fracture and is often considered a late effect of breast cancer treatment. We examined the prevalence of compromised bone health in a sample of exclusively African-American (AA) breast cancer survivors since bone mineral density (BMD) varies by race/ethnicity in healthy populations.

Methods

Using a case–control design, AA women in a weight loss intervention previously diagnosed and treated for stages I–IIIa breast cancer were matched 1:1 on age, race, sex, and BMI with non-cancer population controls (n = 101 pairs) from National Health and Nutrition Examination Survey (NHANES). Questionnaires and dual-energy x-ray absorptiometry (DXA) scanning were completed, and participants were categorized as having normal bone density, low bone mass, or osteoporosis using the World Health Organization (WHO) definition for femoral neck T-scores.

Results

The majority of these overweight/obese survivors were 6.6 (±4.7) years post-diagnosis, had stage II (n = 46) or stage III (n = 16) disease, and treated with chemotherapy (76 %), radiation (72 %), and/or adjuvant hormone therapies (45 %). Mean femoral neck BMD was significantly lower in cases vs. matched non-cancer population controls (0.85 ± 0.15 vs. 0.91 ± 0.14 g/cm2, respectively; p = 0.007). However, the prevalence of low bone mass and osteoporosis was low and did not significantly differ between groups (n = 101 pairs; p = 0.26), even when restricted to those on adjuvant hormone therapies (n = 45 pairs; p = 0.75). Using conditional logistic regression, controlling for dietary factors and education, the odds of developing compromised bone health in AA breast cancer survivors was insignificant (OR 1.5, 95 % CI 0.52, 5.56).

Conclusions

These null case–control findings challenge the clinical assumption that osteoporosis is highly prevalent among all breast cancer survivors, providing foundational evidence to support differences by race/ethnicity and body weight.

Implications for Cancer Survivors

Routine bone density testing and regular patient–provider dialogue is critical in overweight/obese AA breast cancer survivors to ensure that healthy lifestyle factors (e.g., ideal weight, regular weight-bearing exercises, dietary adequacy of calcium and vitamin D) support optimal skeletal health.
Literatur
3.
Zurück zum Zitat Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29(11):2520–6. doi:10.1002/jbmr.2269.PubMedCrossRef Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29(11):2520–6. doi:10.​1002/​jbmr.​2269.PubMedCrossRef
7.
Zurück zum Zitat Chen Z, Maricic M, Pettinger M, Ritenbaugh C, Lopez AM, Barad DH, et al. Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer. Cancer. 2005;104(7):1520–30. doi:10.1002/cncr.21335.PubMedCrossRef Chen Z, Maricic M, Pettinger M, Ritenbaugh C, Lopez AM, Barad DH, et al. Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer. Cancer. 2005;104(7):1520–30. doi:10.​1002/​cncr.​21335.PubMedCrossRef
8.
Zurück zum Zitat Lindsey AM, Gross G, Twiss J, Waltman N, Ott C, Moore TE. Postmenopausal survivors of breast cancer at risk for osteoporosis: nutritional intake and body size. Cancer Nurs. 2002;25(1):50–6.PubMedCrossRef Lindsey AM, Gross G, Twiss J, Waltman N, Ott C, Moore TE. Postmenopausal survivors of breast cancer at risk for osteoporosis: nutritional intake and body size. Cancer Nurs. 2002;25(1):50–6.PubMedCrossRef
9.
Zurück zum Zitat Twiss JJ, Waltman N, Ott CD, Gross GJ, Lindsey AM, Moore TE. Bone mineral density in postmenopausal breast cancer survivors. J Am Acad Nurse Pract. 2001;13(6):276–84.PubMedCrossRef Twiss JJ, Waltman N, Ott CD, Gross GJ, Lindsey AM, Moore TE. Bone mineral density in postmenopausal breast cancer survivors. J Am Acad Nurse Pract. 2001;13(6):276–84.PubMedCrossRef
10.
12.
Zurück zum Zitat Institute of Medicine of the National Academies. Dietary reference intakes for calcium and vitamin D. Washington, DC. Report Brief; 2010. Available at: www.iom.edu. Accessed 23 March 2015. Institute of Medicine of the National Academies. Dietary reference intakes for calcium and vitamin D. Washington, DC. Report Brief; 2010. Available at: www.​iom.​edu. Accessed 23 March 2015.
13.
Zurück zum Zitat Neuhouser ML, Sorensen B, Hollis BW, Ambs A, Ulrich CM, McTiernan A et al. Vitamin D insufficiency in a multiethnic cohort of breast cancer survivors. Am J Clin Nutr. 2008;88(1):133–9. doi: 88/1/133. Neuhouser ML, Sorensen B, Hollis BW, Ambs A, Ulrich CM, McTiernan A et al. Vitamin D insufficiency in a multiethnic cohort of breast cancer survivors. Am J Clin Nutr. 2008;88(1):133–9. doi: 88/1/133.
15.
Zurück zum Zitat Ansell D, Grabler P, Whitman S, Ferrans C, Burgess-Bishop J, Murray LR, et al. A community effort to reduce the black/white breast cancer mortality disparity in Chicago. Cancer Causes Control. 2009;20(9):1681–8. doi:10.1007/s10552-009-9419-7.PubMedCrossRef Ansell D, Grabler P, Whitman S, Ferrans C, Burgess-Bishop J, Murray LR, et al. A community effort to reduce the black/white breast cancer mortality disparity in Chicago. Cancer Causes Control. 2009;20(9):1681–8. doi:10.​1007/​s10552-009-9419-7.PubMedCrossRef
17.
Zurück zum Zitat Mares-Perlman JA, Klein BE, Klein R, Ritter LL, Fisher MR, Freudenheim JL. A diet history questionnaire ranks nutrient intakes in middle-aged and older men and women similarly to multiple food records. J Nutr. 1993;123(3):489–501.PubMed Mares-Perlman JA, Klein BE, Klein R, Ritter LL, Fisher MR, Freudenheim JL. A diet history questionnaire ranks nutrient intakes in middle-aged and older men and women similarly to multiple food records. J Nutr. 1993;123(3):489–501.PubMed
20.
Zurück zum Zitat Bonnick S, editor. Bone densitometry in clinical practice. New York: Humana Press; 2010. Bonnick S, editor. Bone densitometry in clinical practice. New York: Humana Press; 2010.
21.
Zurück zum Zitat Lu Y, Fuerst T, Hui S, Genant HK. Standardization of bone mineral density at femoral neck, trochanter and Ward’s triangle. Osteoporos Int J Established Result Cooperation Between Eur Found Osteoporos Natl Osteoporos Found USA. 2001;12(6):438–44. doi:10.1007/s001980170087.CrossRef Lu Y, Fuerst T, Hui S, Genant HK. Standardization of bone mineral density at femoral neck, trochanter and Ward’s triangle. Osteoporos Int J Established Result Cooperation Between Eur Found Osteoporos Natl Osteoporos Found USA. 2001;12(6):438–44. doi:10.​1007/​s001980170087.CrossRef
22.
Zurück zum Zitat Looker AC, Orwoll ES, Johnston Jr CC, Lindsay RL, Wahner HW, Dunn WL, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Mineral Res Off J Am Soc Bone Mineral Res. 1997;12(11):1761–8. doi:10.1359/jbmr.1997.12.11.1761.CrossRef Looker AC, Orwoll ES, Johnston Jr CC, Lindsay RL, Wahner HW, Dunn WL, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Mineral Res Off J Am Soc Bone Mineral Res. 1997;12(11):1761–8. doi:10.​1359/​jbmr.​1997.​12.​11.​1761.CrossRef
23.
Zurück zum Zitat Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(7):1051–7. doi:10.1200/JCO.2007.11.0726.CrossRef Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(7):1051–7. doi:10.​1200/​JCO.​2007.​11.​0726.CrossRef
24.
Zurück zum Zitat Lonning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(22):5126–37. doi:10.1200/JCO.2005.07.097.CrossRef Lonning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(22):5126–37. doi:10.​1200/​JCO.​2005.​07.​097.CrossRef
25.
Zurück zum Zitat Gibson R. Principles of nutrition assessment. 2nd ed. New York: Oxford University Press; 2005. Gibson R. Principles of nutrition assessment. 2nd ed. New York: Oxford University Press; 2005.
28.
Zurück zum Zitat Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(5):486–92. doi:10.1200/JCO.2006.08.8617.CrossRef Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(5):486–92. doi:10.​1200/​JCO.​2006.​08.​8617.CrossRef
29.
Zurück zum Zitat Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45–53. doi:10.1016/S1470-2045(07)70385-6.PubMedCrossRef Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45–53. doi:10.​1016/​S1470-2045(07)70385-6.PubMedCrossRef
30.
Zurück zum Zitat Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial (18233230). J Bone Miner Res. 2006;21(8):1215–23. doi:10.1359/jbmr.060508.PubMedCrossRef Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial (18233230). J Bone Miner Res. 2006;21(8):1215–23. doi:10.​1359/​jbmr.​060508.PubMedCrossRef
31.
32.
Zurück zum Zitat Barrett-Connor E, Siris ES, Wehren LE, Miller PD, Abbott TA, Berger ML, et al. Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res. 2005;20(2):185–94. doi:10.1359/JBMR.041007.PubMedCrossRef Barrett-Connor E, Siris ES, Wehren LE, Miller PD, Abbott TA, Berger ML, et al. Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res. 2005;20(2):185–94. doi:10.​1359/​JBMR.​041007.PubMedCrossRef
35.
Zurück zum Zitat Wagner DR, Heyward VH. Measures of body composition in blacks and whites: a comparative review. Am J Clin Nutr. 2000;71(6):1392–402.PubMed Wagner DR, Heyward VH. Measures of body composition in blacks and whites: a comparative review. Am J Clin Nutr. 2000;71(6):1392–402.PubMed
37.
Zurück zum Zitat Finkelstein JS, Sowers M, Greendale GA, Lee ML, Neer RM, Cauley JA, et al. Ethnic variation in bone turnover in pre- and early perimenopausal women: effects of anthropometric and lifestyle factors. J Clin Endocrinol Metab. 2002;87(7):3051–6.PubMedCrossRef Finkelstein JS, Sowers M, Greendale GA, Lee ML, Neer RM, Cauley JA, et al. Ethnic variation in bone turnover in pre- and early perimenopausal women: effects of anthropometric and lifestyle factors. J Clin Endocrinol Metab. 2002;87(7):3051–6.PubMedCrossRef
43.
Zurück zum Zitat Wilkins CH, Goldfeder JS. Osteoporosis screening is unjustifiably low in older African-American women. J Natl Med Assoc. 2004;96(4):461–7.PubMedPubMedCentral Wilkins CH, Goldfeder JS. Osteoporosis screening is unjustifiably low in older African-American women. J Natl Med Assoc. 2004;96(4):461–7.PubMedPubMedCentral
44.
Zurück zum Zitat Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, et al. NCCN task force report: bone health in cancer care. J Natl Compr Cancer Netw JNCCN. 2009;7(3):S1–32. quiz S3-5.PubMed Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, et al. NCCN task force report: bone health in cancer care. J Natl Compr Cancer Netw JNCCN. 2009;7(3):S1–32. quiz S3-5.PubMed
45.
Zurück zum Zitat Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(6):967–75. doi:10.1200/JCO.2009.24.5902.CrossRef Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(6):967–75. doi:10.​1200/​JCO.​2009.​24.​5902.CrossRef
46.
Zurück zum Zitat Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar R, et al. NCCN task force report: bone health in cancer care. J Natl Compr Cancer Netw JNCCN. 2013;11(3):S1–50. quiz S1.PubMed Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar R, et al. NCCN task force report: bone health in cancer care. J Natl Compr Cancer Netw JNCCN. 2013;11(3):S1–50. quiz S1.PubMed
Metadaten
Titel
Assessing the prevalence of compromised bone health among overweight and obese African-American breast cancer survivors: a case–control study
verfasst von
Patricia Sheean
Huifang Liang
Linda Schiffer
Claudia Arroyo
Karen Troy
Melinda Stolley
Publikationsdatum
01.02.2016
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 1/2016
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-015-0448-9

Weitere Artikel der Ausgabe 1/2016

Journal of Cancer Survivorship 1/2016 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.